secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-076553
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Personalis reports 400% clinical test volume growth in 2025, guides $78-80M FY2026 revenue
--------------------------------------------------------------------------------

- Clinical volume surged 400% YoY to 16,233 tests; Q4 sequential growth 41% to 6,183 tests.
- Total FY2025 revenue $69.6M (down 18% YoY); clinical test revenue more than doubled to $2.0M.
- Ended 2025 with ~$240M cash, including $109M net from ATM at $8.43/share average.
- Secured Medicare coverage for breast and lung cancer surveillance; key catalyst for MRD.
- FY2026 guidance: total revenue $78-80M, clinical revenue $10-11M (5x growth), net loss ~$105M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000119312526076553/0001193125-26-076553-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000119312526076553/psnl-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-076553

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer